Hanmi Pharmaceuticals (Hanmi Pharmaceutical Co Ltd., www.hanmipharm.com ) invested 152.5 billion Korean won (KRW) in the research and development (R&D) last year, which is the largest amount of investment ever.
On February 6, Hanmi(President&CEO Dr.Lee Gwan-Sun) released its preliminary results in 2014 based on International Financial Reporting Standards (IFRS): 761.2 billion KRW of accumulated revenue (4.3%), 34.4 billion KRW of operating profit (-44.3%) and 43.2 billion KRW of net income (-14.3%).
It shows an upward trend in profit rate due to expanded exports of finished medicine and medical supplies offsetting the decrease in operating profit caused by its additional investment of about 40 billion KRW in R&D compared to 2013.
Such an aggressive investment in R&D made Hanmi Pharmaceuticals achieve remarkable outcomes like clinical trials of its Quantum project (antidiabetic pipeline) and license-out contracts of Poziotinib.
Meanwhile, Beijing Hanmi Pharmaceuticals(北京韩美药品有限公司), Hanmi’s affiliate in China recorded sales of RMB .1052 billion(+5.3%), operating profit of RMB149.67 million(-1.4%), net profit of RMB135.49 million, while Hanmi Fine Chemical reported its revenue of RMB90.6 billion, operating profit of RMB5.3 billion and net profit of RMB4.9 billion(+290.4%).
